Nephros Receives 510(k) Clearance for Hemodiafiltration System
Nephros, Inc. (OTC: NEPH) today announced the Company has received 510(k) clearance from the Food and Drug Administration to market its Hemodiafiltration system for the treatment of chronic renal failure when used with UF controlled dialysis machines capable of producing ultrapure dialysate in accordance with current AAMI/ANSI/ISO standards in the United States.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.